Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GRTS | US
-0.01
-31.78%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.03
0.04
0.04
0.03
Gritstone bio Inc. a clinical-stage biotechnology company engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE a neoantigen-based immunotherapy which is in Phase 2/3 clinical trials for the treatment of solid tumors including microsatellite stable colorectal cancers. The company is also developing SLATE an off-the-shelf immunotherapy candidate which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition it develops CORAL a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio Inc. has a strategic collaboration with bluebird bio Inc.; collaboration agreement with Gilead Sciences Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology Inc. and changed its name to Gritstone bio Inc. in May 2021. Gritstone bio Inc. was incorporated in 2015 and is headquartered in Emeryville California.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
391.8%1 month
352.3%3 months
218.1%6 months
167.2%-
-
0.25
4.62
0.72
-0.91
105.56
-
-129.23M
3.80M
3.80M
-
-3.00K
-
-52.90
-201.94
6.24
6.51
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.20
Range1M
0.63
Range3M
0.66
Rel. volume
1.17
Price X volume
1.96M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
NuCana plc | NCNA | Biotechnology | 1.86 | 4.18M | -1.06% | n/a | 0.00% |
Fresh America Corp | FRES | Biotechnology | 1.66 | 4.07M | -15.74% | n/a | 0.22% |
Lipella Pharmaceuticals Inc. Common Stock | LIPO | Biotechnology | 0.4896 | 3.97M | -0.99% | n/a | 5.50% |
Windtree Therapeutics Inc | WINT | Biotechnology | 1.07 | 3.94M | 17.16% | n/a | 36.99% |
Genprex Inc | GNPX | Biotechnology | 1.51 | 3.91M | 265.62% | n/a | 0.00% |
InMed Pharmaceuticals Inc | INM | Biotechnology | 0.29 | 3.87M | 21.04% | n/a | 7.00% |
Neurotrope Inc | NTRP | Biotechnology | 2.4 | 3.80M | 0.00% | n/a | 0.00% |
Sonnet BioTherapeutics Holdings Inc | SONN | Biotechnology | 5.71 | 3.71M | -3.38% | n/a | 5.74% |
Oragenics Inc | OGEN | Biotechnology | 0.345 | 3.63M | 5.83% | n/a | 0.00% |
Virpax Pharmaceuticals Inc | VRPX | Biotechnology | 0.7216 | 3.53M | 6.15% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.91 | 0.53 | Cheaper |
Ent. to Revenue | 105.56 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 0.25 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 218.12 | 72.80 | Riskier |
Debt to Equity | 4.62 | -1.23 | Expensive |
Debt to Assets | 0.72 | 0.25 | Expensive |
Market Cap | 3.80M | 3.66B | Emerging |